Immunotherapy first, then kidney surgery for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have clear cell kidney cancer (or mostly clear cell).
- Your cancer has spread to other parts of your body (metastatic) or to lymph nodes, but you have no more than 5 spots of spread affecting up to 3 organs.
- You are 18 to 79 years old and in good overall health (able to do daily activities with little or no help).
- Your kidney function, liver function, and heart are working well (no major problems).
- You have not had any other cancer in the last 5 years, except for certain skin cancers or cervical cancer that was cured.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This study tests a combination of two drugs (toripalimab and axitinib) as the first treatment for advanced kidney cancer that has clear cell features. The goal is to see if this drug combo can shrink tumors and possibly allow some patients to avoid or delay surgery to remove the kidney. Participation requires a tumor biopsy that shows a specific immune pattern.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This study looks at whether people with metastatic kidney cancer can be managed with standard immune-based treatment and then have their main kidney tumor removed. It is meant for people who can have surgery and whose cancer has not grown at the time this approach is considered.
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
Hear when a new Clear-cell Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.